豪赌新冠疫苗无果,国产疫苗公司陷2.24亿美元纠纷

谈思生物
Mar 25, 2025

2025.03.25本文字数:1060,阅读时长大约3分钟导读:港股上市公司三叶草生物面临重大危机!其与全球疫苗免疫联盟(Gavi)的新冠疫苗预购协议被单方面终止,Gavi要求退还2.24亿美元预付款。三叶草生物拒绝退款,双方陷入僵局,公司资金链紧张,转型开发的RSV疫苗能否成为救命稻草?当一家市值仅约4亿多港元的小型生物科技公司,面临客户高达2.24亿美元的退款要求时,这无疑是一个巨大的挑战。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10